A B S T R A C T Immunoreactive calcitonin released by a medullary thyroid carcinoma in tissue culture has been found to exhibit heterogeneity when analyzed by gel chromatography and radioimmunoassay, in a pattern analogous to that seen in the circulation of the patient from whom the neoplasm was removed. To examine the cause of the heterogeneity, the immunoreactive material released by the tumor into tissue culture medium was further analyzed by gel electrophoresis in the presence of the protein denaturant 8 M urea, by gel chromatography after reduction and alkylation, by affinity chromatography oIn concanavalin A-agarose, and by bioassay in a renal adenylyl cyclase system of enhanced sensitivity. The results suggest that the larger immunochemical forms of calcitonin described in the circulation of patients with medullary thyroid carcinoma may be released directly from the neoplasm and need not derive from peripheral metabolism of the monomer. It could be demonstrated that a major proportion of the immunochemical enlargement is dependent upon intermolecular disulfide bridge formation whereas aggregation or non-convalent protein binding account for a smaller component of the heterogeneity. In view of the absence of binding of the immunoreactive material to the lectin agarose, carbohydrate side chains, at least of INTRODUCTION Calcitonin in several species is known to be a 32-amino acid polypeptide hormone (1) (2) (3) (4) (5) (6) containing an intrachain disulfide bridge between sequence positions 1 and 7 at the NH2-terminal end of the molecule and an amide group on the COOH-terminal proline. The human hormone (hCT)' is secreted by normal (7) (8) (9) (10) (11) (12) and neoplastic C cells (7) (8) (9) (10) (11) (12) (13) (14) (15) , as well as by non-C cell neoplasms (16) (17) (18) . It has been established that immunochemical heterogeneity of calcitonin exists (19) (20) (21) in body fluids of patients with medullary thyroid carcinoma and non-C cell neoplasms. This heterogeneity, defined by gel chromatography and radioimmunoassay techniques, consists mainly of larger forms of the conventional calcitonin monomer. There is little information, however, as to the basis of this heterogeneity; that is, it is unknown whether the "larger" immunochemical forms represent aggregates of the monomer, non-covalent binding of the monomer to another protein, high molecular weight complexes of calcitonin formed by disulfide bridge formation, or covalent extensions of the monomer. Furthermore, there is no information as to the biological activity of these other molecular species. The present studies were undertaken to characterize the forms of immunoreactive calcitonin released into culture medium by a medullary thyroid carcinoma maintained in tissue culture. Both physicochemical and biological properties of the immunoreactive material were investigated.
METHODS
Source ofsamples. Plasma samples and medullary thyroid carcinoma tissue were obtained at the time of surgery from a 55-year-old male with familial medullary thryoid carcinoma as a part of the multiple endocrine neoplasia syndrome (22 Radioimmunoassay. The radioimmunoassay for calcitonin employed in these studies is similar to that previously described (23, 24) . Antiserum was raised in rabbits to synthetic human calcitonin monomer. The same synthetic peptide was also used for radioimmunoassay standard and for radioiodination. Radioimmunoassay buffer consisted of a solution of0.03 M sodium phosphate buffer at pH 7.0, 0.001 M disodium EDTA, 0.005% (wt/vol) merthiolate, and 10% (vol/ vol) athyreotic plasma or outdated blood bank plasma (previously tested for absence of immunoreactive calcitonin and extent of damage to tracer). Unknown samples were assayed in duplicate or triplicate and often in multiple dilutions. Each 0.5-ml incubation volume contained no more than 20% (vol/vol) plasma. Synthetic peptide fragments employed for characterization of the antiserum were kindly supplied by Drs. W. Rittel and R. Maier, Ciba-Geigy Ltd., and Dr. F. R. Singer, University of Southern California.
Gelfiltration. Gel filtration studies were performed at 40C (for bioassay studies) or 22°C (for studies employing guanidine-HCl) with 1.5 x 70-cm columns of Bio-Gel P-100 (100-200 mesh, Bio-Rad Laboratories, Richmond, Calif.) eluted with 0.1 M ammonium acetate buffer, pH 5.0. 13"Ilabeled calcitonin monomer and 131I-Na were added to each 1-ml sample of plasma or 4-ml sample of culture medium immediately before gel filtration to serve as internal markers of the hormone monomer and salt peak respectively. 131I_ counts were determined for each eluted 0.9-ml fraction, in a gamma well spectrometer (Packard Instrument Co., Inc., Downers Grove, Ill.). Each fraction was then lyophylized, reconstituted in 0.2 ml radioimmunoassay buffer, and assayed in duplicate. For studies analyzing reduced and alkylated hormone, column calibration was performed with the tritiated S-carboxymethylcysteine derivative of calcitonin monomer (vida infra) and no 131I-labeled internal standards were added. 3H radioactivity in 0. l-ml aliquots of each eluted fraction was determined in a liquid scintillation spectrometer (Packard Instrument Co., Inc.), whereas the remainder of the aliquots was lyophilized and then assayed for immunoreactivity. For assessment of apparent molecular weight, ovalbumin, chymotrypsinogen A, ribonuclease A (all from Pharmacia Fine Chemicals, Div. of Pharmacia, Inc., Uppsala, Sweden), bovine serum albumin (Sigma Chemical Co., St. Louis, Mo.), human growth hormone (courtesy of the National Pituitary Agency), and bovine parathyroid hormone (courtesy of Dr. J. T. Potts, Jr., Massachusetts General Hospital) were employed for column calibration.
Gel electrophoresis. 0.2-ml aliquots of fractions obtained by gel filtration of medullary carcinoma tissue culture medium were combined into four pools (the pool sizes having been determined by radioimmunoassay of the remainder of each fraction). The pools were then lyophilized, and each pool was reconstituted in 0.2 ml of a solution of 8 M urea-0.1 M acetic acid, and incubated with intermittent stirring for 30 min at 22°C before electrophoresis at pH 4.4 on 8% urea-polyacrylamide gels at 4°C. 1311_ labeled calcitonin monomer was employed as a marker. Gels were cut into 1-mm slices, and each slice was shaken for 24 h at 4°C in 0.2 ml of radioimmunoassay buffer. Each 0.2-ml sample was then assayed for 131I radioactivity and analyzed by radioimmunoassay.
Reduction and alkylation. Lyophilized pools of immunoreactive calcitonin obtained by gel filtration of medullary carcinoma tissue culture medium or lyophilized synthetic human calcitonin monomer were each dissolved in 0.2 ml of a solution of 6 M guanidine-HCl in 0.05 M Tris-HCl, pH 8.5, gassed with N2, sealed, and then incubated with shaking at 37°C for 1 h to denature the protein. Dithiothreitol (Sigma Chemical Co.) was then added to the mixture to a final concentration of 0.0015 mM, and the mixture was gassed with N2 and shaken for 4 more h at 37°C. A solution of 0.2 ml of 0.0075 mM iodoacetic acid (Sigma Chemical Co.) in 2 M Tris-HCl, pH 8.5, was then added to the calcitonin-guanidine-dithiothreitol mixture, and the combined mixtures were incubated in the dark at 22°C for 30 min. Then the reaction was stopped by the addition of 0.1 ml /-mercaptoethanol. The entire mixture was chromatographed on Bio-Gel P-100, and each fraction was radioimmunoassayed as described previously.
In initial experiments involving synthetic human calcitonin monomer, 10-20 x 106 cpm of [2-3H] iodoacetic acid (specific activity 64 mCi/mmol; Amersham/Searle Corp., Arlington Heights, Ill.) was added to the alkylating solution. The Scarboxymethylcysteine derivative of the calcitonin monomer with incorporated 3H, was desalted on a column of Bio-Gel P-2 (100-200 mesh, Bio-Rad Laboratories) and was employed as a column marker for the alkylated monomer in subsequent reduction and alkylation studies with immunoreactive pools. In preliminary experiments, it was determined that synthetic human calcitonin monomer, after reduction and alkylation by the procedure just described, reacted with the antiserum used in these studies in parallel with the synthetic human calcitonin monomer standard.
Affinity chromatography. Lyophilized pools of immunoreactive calcitonin obtained by gel filtration of medullary carcinoma tissue culture medium or lyophilized synthetic human calcitonin monomer were each dissolved in 0.5 ml of 1.0 MI ammonium acetate buffer, pH 6.0, containing 1 mM CaCl2, 1 mM\N MgCl2, and 1 mM\l MnCl2. Each 0.5-ml sample was applied separately at 22°C to an 0.3-ml column of concanavalin A-agarose (Sigma Chemical Co.), prepared in a Pasteur pipette. The column was then eluted with an 0.5-ml vol of buffer followed by nine 1-ml aliquots of buffer. Four 1-ml vol of buffer containing 0.2 M a-methyl D-mannopyranoside (Aldrich Chemical Co., Inc., Milwaukee, Wis.) were then added to elute specifically-bound material. The column was then washed with 4 more 1-ml aliquots of buffer without glycoside. 31I-labeled calcitonin monomer, or 1311-labeled human thyroid-stimulating hormone (National Pituitary Agency) was added to each sample chromatographed to serve as an internal control. 1311 radioactivity was determined in each eluted fraction which was then lyophilized, reconstituted in radioimmunoassay buffer, and radioimmunoassayed for calcitonin.
Adenrylyl cyclase assay. Adenylyl cyclase activity was determined in purified renal membranes prepared from the kidneys of male albino (New Zealand) rabbits, 15-17 kg, or of male Sprague-Dawley rats, 150-200 g, according to a method previously described (25, 26) . In preliminary experiments, the adenylyl cyclase assay when performed in membranes prepared from rabbit kidneys, was found to be 13-fold more sensitive to synthetic hCT monomer than was the assay performed in conventional rat renal membranes; consequently, rabbit membranes were employed for subsequent studies. Adenylyl cyclase activity was determined (27) 
RESULTS
Antiserum specificity. The synthetic hCT fragment representing sequence positions 17-28 produced minimal inhibition of binding of 125I-labeled hCT , the intact monomer, to the antiserum (Fig. 1) . The hCT fragment extended towards the NH2-terminus by six residues and, in representing sequence positions 11-28, produced more marked, but still incomplete, inhibition of hCT monomer binding to the antiserum (Fig. 1) . However, inclusion of the four COOHterminal residues, in the fragment representing sequence positions 17-32, resulted in marked inhibition of binding of the intact labeled monomer to the antiserum (Fig. 1) . Nevertheless, twice the concentration of this latter fragment as of the intact monomer was required to produce 50% inhibition, and the displacement was nonparallel. Inclusion of both the six more NH2-terminal residues, as well as the four residues at the COOH-terminus, in the fragment representing sequence positions 11-32, achieved inhibition of binding of labeled intact monomer to the antiserum which was both parallel and equimolar with the unlabeled intact monomer standard (Fig. 1) .
Consequently, the antiserum appeared to require primarily a major antigenic site within sequence positions 29-32 at the COOH-terminus of hCT monomer, and a minor antigenic site in the middle of the molecule within sequence positions [11] [12] [13] [14] [15] [16] . Whether the residues within these sites interact directly with antibody sequences or produce a molecular conformation appropriate for antibody recognition could not be distinguished by these studies.
Gel filtration of plasma and tissue culture mediuml calcitonin. Patient plasma and medullary carcinoma tissue culture medium contained 21 and 48 ng/ml of immunoreactive calcitonin, respectively, and recoveries of total immunoreactivity after gel filtration were 63 and 71%, respectively. Both elution profiles demonstrated multiple "peaks and shoulders" of immunoreactivity (Fig. 2 , panels a and b) but appeared qualitatively similar in the overall pattern of distribution of eluted immunoreactivity. In each case, only one peak of immunoreactivity co-eluted with the 1311_ labeled hCT monomer; the remaining immunoreactivity eluted before the monomer. However, quantitative differences in the major eluted regions of immunoreactivity were apparent with, for example, a greater proportion of the total immunoreactivity of plasma than of tissue culture medium co-eluting with 131I-labeled hCT monomer (28% vs. 24%, respectively). In contrast, in control experiments incubating synthetic human calcitonin monomer with either calcitonin-free plasma or with non-calcitonin-producing cells (fibroblast cells) in tissue culture, virtually all immunoreactivity co-eluted with the hCT monomer marker (Fig. 2, panels c and d) .
For further analysis of the calcitonin immunoreactivity released into the medullary carcinoma tissue culture medium, the immunoreactive material obtained by gel chromatography was combined into four major pools, I-IV (Fig. 2b) : pool I included material having apparent molecular weights > 60,000 (Kd 0-0.11); pool II included material having apparent molecular weights in the 13,000-40,000 range (Kd 0.21-0.48); pool III included material having apparent molecular weights in the 4,000-13,000 range (Kd 0.48-0.72); and pool IV included material coeluting with calcitonin monomer (Kd 0.72-0.83). Although any of these four major pools in themselves may have represented heterogeneous entities, the absence of biochemical information regarding their precise identity seemed to minimize any advantage which might have been gained by further subfractionating them. Consequently, these pools were used as the starting (K) and 11-32 (0). OH represents the free carboxyl group at the COOH-terminus, and NH2
an amide group on the COOH-terminal residue. B and F refer to quantities of antibody-bound and free 125I-labeled hCT, respectively. Initial B/F was 0.74.
point for the characterization of the calcitonin immunoreactivity released by the tumor. Serial dilutions of aliquots of medullary carcinoma culture medium before gel filtration and of aliquots of each eluted pool obtained by gel filtration inhibited 125I-labeled HCT monomer binding to the antiserum in parallel with the hCT monomer standard (Fig. 3) . Consequently, quantitation of each pool was possible in terms of nanograms of hCT monomer. Each of pools I-IV represented 13, 15, 38 , and 24%, respectively, of recovered immunoreactivity. The binding inhibition in parallel with hCT standard displayed by each eluted pool of immunoreactivity, indicated that each pool contained sufficient antigenic determinants to satisy at least the spatially discrete sites required for the interaction of the antiserum with hCT monomer.
Electrophoretic analysis. When each pool of calcitonin immunoreactivity obtained by gel filtration of medullary carcinoma medium was analyzed by polyacrylamide gel electrophoresis and radioimmunoassay, each pool was found to be heterogenous; that is, the immunoreactivity did not resolve into a single peak comigrating with the 1251-labeled calcitonin monomer despite the presence of the protein denaturant 8 M urea (Fig. 4) . Nevertheless, in pools I-III, a significant proportion of the immunoreactivity co-migrated with the hCT monomer marker (23, 26 , and 16% of recovered immunoreactivity, respectively); only in pool IV, however, did the bulk of the immunoreactivity (79%) co-migrate with the monomer marker. Consequently, despite analysis in the presence of the protein denaturant, immunochemical heterogeneity persisted (Fig. 4) 5 Gel filtration profiles of calcitonin immunoreactivity after chromatography on BioGel P-100 of reduced and alkylated pools I to IV. Each pool initially obtained by gel filtration of medullary carcinoma tissue culture medium, was reduced with dithiothreitol in 6 M guanidine-HCl under N2 at 37°C and then alkylated with iodoacetic acid before rechromatography. Vertical arrows, from left to right, represent the void volume (Vo), the elution position of the reduced and alkylated hCT monomer labeled with [2-3H] (34) and has been demonstrated to stimulate adenylyl cyclase in membranes prepared from rat kidneys in vitro (35, 36) . Consequently, this defined property of calcitonin of stimulating in vitro adenylyl cyclase was used as a bioassay in the present studies. Rabbit renal membranes were employed rather than rat membranes in view of their enhanced sensitivity to human calcitonin. Only pool IV, corresponding to the human calcitonin monomer, could be demonstrated to stimulate adenylyl cyclase significantly. Consequently, insofar as the assay reflects in vivo activity, the majority of the immunoreactivity released by a medullary thyroid carcinoma, at least in vitro, may be biologically inactive or of markedly reduced activity relative to the monomer.
Studies correlating calcitonin structure with function have demonstrated that an intact disulfide bridge between sequence positions 1 and 7 of the monomer is essential for biological activity (37) , and, indeed, the dimer previously extracted from tumor tissue was demonstrated to have little activity until converted to monomer (38) . This, therefore, may explain the absence of detectable activity in pool I in which the intramolecular disulfide bridge would no longer have remained intact.
The precise nature of the majority of pools II within these pools would be the most likely to represent covalent extensions of calcitonin monomer possibly functioning as biosynthetic precursors. Biosynthetic precursors of peptide hormones are frequently reported to have reduced biological activity relative to the hormonal products (39, 40) . Of the two studies which have reported the existence of precursors of calcitonin, one did not assess the biological activity of the precursor (molecular weight 7,000) derived from trout ultimobranchial glands (41) , but the other study did report reduced activity (relative to monomer) of a precursor (molecular weight about 13,000) derived from chicken ultimobronchial glands (42) . Consequently, the discordance between immunologic and biologic activity seen in our studies may be related to the observations regarding bio-activity reported for peptide hormone precursors including calcitonin precursors.
Further studies will be required to determine more precise chemical and biological properties ofthe larger forms, and development of specific antisera to them may eventually lead to more sensitive indices of the activity of neoplastic and perhaps of non-neoplastic C cells. 
